reteplase
Protein / enzyme biologic targets PLAT
Regulatory milestones approvals, filings & regulatory actions · 3 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Withdrawn | EU (EMA) | Rapilysin | — | 2024-01-26 | europa.eu ↗ |
| Approved | US (FDA) | RETAVASE | — | 1998-05-06 | fda.gov ↗ |
| Approved | EU (EMA) | Rapilysin | — | 1996-08-29 | europa.eu ↗ |
Trials 16 · a red edge is where a trial was stopped
Also used as a comparator or background therapy in 1 trial
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 4 | NCT00806403 Comparator | Nov 2001 → Jun 2003 | acute myocardial infarction | Sahlgrenska University Hospital | Completed | No outcome recorded |
Evidence & citations 13 cited values
Every value below carries the sentence it was read from. 18 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Reteplase | “The GUSTO (Global Use of Strategies to Open Occluded Arteries in Acute Coronary Syndromes) V Investigators studied standard-dose reteplase vs standard-dose abciximab plus...” PMID 17954798 ↗ Oct 200715“Recombinant human tissue-type plasminogen activator derivative(rPA,chemical name: Reteplase,brand name:Ruitongli) 18mg/10ml/stick, provided by AngDe Biotech Pharmaceutical...” NCT04110275 ↗ “This clinical trial will determine an acceptable dose of reteplase in combination with a fixed dose of abciximab for ischemic stroke” NCT00046293 ↗ “intravenous reteplase (a bolus of 18 mg followed by a second bolus of 18 mg after 30 minutes)” NCT06841965 ↗ “intravenous reteplase (a bolus of 18 mg followed by a second bolus of 18 mg after 30 minutes)” NCT06115070 ↗ “intravenous reteplase (a bolus of 18 mg followed by a second bolus of 18 mg after 30 minutes)” NCT06749834 ↗ “Reteplase is a more affordable new-generation thrombolytic with a prolonged half-life.” PMID 38152962 ↗ Dec 2023 “Reteplase versus Alteplase for Acute Ischemic Stroke.” PMID 42089199 ↗ May 2026 “intravenous reteplase (a bolus of 18 mg” NCT06841978 ↗ “Reteplase” NCT03594175 ↗ |
| Known as | BM 06.022 | ChEMBL registry synonym — accepted as the source's own label CHEMBL2107885 ↗ |
| Known as | CUSA-081 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03992443 ↗ |
| Known as | Ecokinase | ChEMBL registry synonym — accepted as the source's own label CHEMBL2107885 ↗ |
| Known as | Rapilysin | ChEMBL registry synonym — accepted as the source's own label CHEMBL2107885 ↗ |
| Known as | RETAVASE | “This study will evaluate the safety and effectiveness of two types of blood thinners, abciximab (ReoPro) and reteplase (Retavase) for restoring normal brain blood flow after...” NCT00039832 ↗1“The study aims to evaluate third-generation thrombolytic - RETAVASE® (reteplase) and compare it to IV alteplase, in acute ischemic stroke patients.” NCT05900674 ↗ |
| Known as | Reteplasa | ChEMBL registry synonym — accepted as the source's own label CHEMBL2107885 ↗ |
| Known as | Reteplase, recombinant | ChEMBL registry synonym — accepted as the source's own label CHEMBL2107885 ↗ |
| Known as | Retevase | ChEMBL registry synonym — accepted as the source's own label CHEMBL2107885 ↗ |
| Known as | rPA | “Recombinant human tissue-type plasminogen activator derivative(rPA,chemical name: Reteplase,brand name:Ruitongli) 18mg/10ml/stick, provided by AngDe Biotech Pharmaceutical...” NCT04110275 ↗ |
| Modality | Protein / enzyme biologic | “CUSA-081 (reteplase) is a recombinant tissue plasminogen activator (tPA)” NCT03594175 ↗ |
| Route | Intravenous | “Retavase is administered in a single dose through a needle in the vein over 2 minutes.” NCT00039832 ↗ |
| Target | PLAT | “Tissue-type plasminogen activator exogenous protein” CHEMBL2107885 ↗ |